Gene · 6595
Papers3,459
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 3,459
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Epigenetic modulators provide a path to understanding disease and therapeutic opportunity. | Genes Dev | 2024 | 38914477 | PubTator, text mining | PubMed |
| SETMAR Facilitates the Differentiation of Thyroid Cancer by Regulating SMARCA2-Mediated Chromatin Remodeling. | Adv Sci (Weinh) | 2024 | 38900084 | PubTator, text mining | PubMed |
| Blepharophimosis with intellectual disability and Helsmoortel-Van Der Aa Syndrome share episignature and phenotype. | Am J Med Genet C Semin Med Genet | 2024 | 38884529 | PubTator, text mining | PubMed |
| Caudal regression in fetus with de novo SMARCA2 pathogenic variant. | Prenat Diagn | 2024 | 38877377 | PubTator, text mining | PubMed |
| CRISPR activation screens identify the SWI/SNF ATPases as suppressors of ferroptosis. | Cell Rep | 2024 | 38870012 | PubTator, text mining | PubMed |
| Expanding the horizons of targeted protein degradation: A non-small molecule perspective. | Acta Pharm Sin B | 2024 | 38828146 | PubTator, text mining | PubMed |
| Novel therapeutic strategies targeting bypass pathways and mitochondrial dysfunction to combat resistance to RET inhibitors in NSCLC. | Biochim Biophys Acta Mol Basis Dis | 2024 | 38768929 | PubTator, text mining | PubMed |
| Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs. | Commun Med (Lond) | 2024 | 38755248 | PubTator, text mining | PubMed |
| DNA methylation analysis in patients with neurodevelopmental disorders improves variant interpretation and reveals complexity. | HGG Adv | 2024 | 38751117 | PubTator, text mining | PubMed |
| Expanding TPD Horizons: Innovative Strategies Targeting BCL6 and SMARCA2. | ACS Med Chem Lett | 2024 | 38746879 | PubTator, text mining | PubMed |
| Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors - a review of patent literature from 2019-June 2023. | Expert Opin Ther Pat | 2024 | 38742308 | PubTator, text mining | PubMed |
| SWI/SNF-Related SMARCA2 Gene Mutation Associated with Nicolaides-Baraitser's Syndrome: Follow-up Study. | J Pediatr Genet | 2024 | 38721580 | PubTator, text mining | PubMed |
| Oncogenic functions and therapeutic potentials of targeted inhibition of SMARCAL1 in small cell lung cancer. | Cancer Lett | 2024 | 38697461 | PubTator, text mining | PubMed |
| Malignant melanoma arising from giant congenital melanocytic nevus with SMARCA2 gene mutation. | Asian J Surg | 2024 | 38604858 | PubTator, text mining | PubMed |
| Cytomorphology of metastatic colonic MXD4::NUTM1-rearranged sarcoma. | Diagn Cytopathol | 2024 | 38595053 | PubTator, text mining | PubMed |
| Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors - a review of patent literature from 2019-30 June 2023. | Expert Opin Ther Pat | 2024 | 38578210 | PubTator, text mining | PubMed |
| CENPA and BRCA1 are potential biomarkers associated with immune infiltration in heart failure and pan-cancer. | Heliyon | 2024 | 38576566 | PubTator, text mining | PubMed |
| Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer. | Proc Natl Acad Sci U S A | 2024 | 38557192 | PubTator, text mining | PubMed |
| Gene amplification of chromatin remodeling factor SMARCC2 and low protein expression of ACTL6A are unfavorable factors in ovarian high‑grade serous carcinoma. | Oncol Lett | 2024 | 38516682 | PubTator, text mining | PubMed |
| Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer. | bioRxiv | 2024 | 38464081 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6595/papers?page=11